| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Coronary Syndrome | 181 | 2023 | 2337 | 13.060 |
Why?
|
| Platelet Aggregation Inhibitors | 205 | 2023 | 3067 | 11.960 |
Why?
|
| Myocardial Infarction | 414 | 2023 | 11690 | 10.370 |
Why?
|
| Angina, Unstable | 123 | 2021 | 926 | 9.350 |
Why?
|
| Cholesterol, LDL | 89 | 2023 | 2354 | 8.870 |
Why?
|
| Anticholesteremic Agents | 66 | 2023 | 979 | 8.220 |
Why?
|
| Ticlopidine | 100 | 2017 | 899 | 7.840 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 123 | 2023 | 3239 | 7.640 |
Why?
|
| Thrombolytic Therapy | 145 | 2016 | 2161 | 5.730 |
Why?
|
| Fibrinolytic Agents | 106 | 2023 | 2156 | 5.490 |
Why?
|
| Atrial Fibrillation | 56 | 2023 | 5019 | 5.050 |
Why?
|
| Anticoagulants | 65 | 2023 | 4595 | 4.720 |
Why?
|
| Pravastatin | 48 | 2017 | 395 | 4.480 |
Why?
|
| Cardiovascular Diseases | 141 | 2024 | 15108 | 4.450 |
Why?
|
| Angioplasty, Balloon, Coronary | 94 | 2012 | 1873 | 4.250 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 33 | 2023 | 361 | 4.160 |
Why?
|
| Heptanoic Acids | 48 | 2015 | 343 | 4.100 |
Why?
|
| Coronary Artery Disease | 78 | 2023 | 6454 | 3.920 |
Why?
|
| Adenosine | 42 | 2017 | 823 | 3.870 |
Why?
|
| Coronary Disease | 85 | 2021 | 6078 | 3.800 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 56 | 2016 | 641 | 3.780 |
Why?
|
| Simvastatin | 29 | 2021 | 360 | 3.560 |
Why?
|
| Warfarin | 26 | 2021 | 1493 | 3.530 |
Why?
|
| Diabetes Mellitus, Type 2 | 85 | 2023 | 11695 | 3.490 |
Why?
|
| Dyslipidemias | 20 | 2021 | 848 | 3.440 |
Why?
|
| Hypercholesterolemia | 24 | 2023 | 1149 | 3.360 |
Why?
|
| Antithrombins | 9 | 2020 | 304 | 3.310 |
Why?
|
| Aspirin | 80 | 2021 | 3278 | 3.180 |
Why?
|
| Hemorrhage | 59 | 2022 | 3461 | 3.150 |
Why?
|
| Diclofenac | 12 | 2013 | 71 | 3.060 |
Why?
|
| Atherosclerosis | 35 | 2024 | 3428 | 3.030 |
Why?
|
| Pyrroles | 48 | 2015 | 1143 | 2.990 |
Why?
|
| Guideline Adherence | 53 | 2020 | 2266 | 2.700 |
Why?
|
| Myocardial Revascularization | 47 | 2021 | 841 | 2.630 |
Why?
|
| Hypolipidemic Agents | 23 | 2021 | 604 | 2.620 |
Why?
|
| Drug Therapy, Combination | 90 | 2023 | 6483 | 2.590 |
Why?
|
| Uracil | 16 | 2020 | 164 | 2.500 |
Why?
|
| Electrocardiography | 96 | 2018 | 6440 | 2.470 |
Why?
|
| Myocardial Reperfusion | 27 | 2017 | 351 | 2.400 |
Why?
|
| Sulfones | 11 | 2011 | 437 | 2.370 |
Why?
|
| Piperidines | 25 | 2020 | 1602 | 2.360 |
Why?
|
| Critical Pathways | 15 | 2022 | 475 | 2.320 |
Why?
|
| Double-Blind Method | 139 | 2023 | 12017 | 2.300 |
Why?
|
| Stroke | 80 | 2023 | 9963 | 2.180 |
Why?
|
| Practice Guidelines as Topic | 79 | 2019 | 7276 | 2.010 |
Why?
|
| Treatment Outcome | 305 | 2023 | 62966 | 1.960 |
Why?
|
| Serine Proteinase Inhibitors | 4 | 2019 | 179 | 1.950 |
Why?
|
| Humans | 937 | 2024 | 742088 | 1.930 |
Why?
|
| Aged | 467 | 2023 | 162944 | 1.840 |
Why?
|
| Platelet Function Tests | 14 | 2016 | 270 | 1.810 |
Why?
|
| Renal Insufficiency, Chronic | 20 | 2022 | 2195 | 1.810 |
Why?
|
| Secondary Prevention | 38 | 2021 | 1520 | 1.800 |
Why?
|
| Heart Failure | 78 | 2023 | 10856 | 1.800 |
Why?
|
| Middle Aged | 515 | 2023 | 213127 | 1.790 |
Why?
|
| Thrombosis | 33 | 2022 | 2966 | 1.720 |
Why?
|
| Male | 592 | 2023 | 349538 | 1.680 |
Why?
|
| Cholesterol Ester Transfer Proteins | 10 | 2017 | 111 | 1.660 |
Why?
|
| Oxazolidinones | 9 | 2022 | 96 | 1.640 |
Why?
|
| Risk Assessment | 141 | 2024 | 23320 | 1.630 |
Why?
|
| Registries | 83 | 2021 | 8077 | 1.610 |
Why?
|
| Female | 596 | 2023 | 379592 | 1.600 |
Why?
|
| Randomized Controlled Trials as Topic | 103 | 2022 | 9941 | 1.580 |
Why?
|
| Azetidines | 6 | 2015 | 142 | 1.570 |
Why?
|
| Pyridines | 16 | 2017 | 2818 | 1.540 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 12 | 2013 | 2276 | 1.490 |
Why?
|
| Oximes | 17 | 2021 | 309 | 1.460 |
Why?
|
| Heparin | 31 | 2010 | 1636 | 1.440 |
Why?
|
| Coronary Artery Bypass | 31 | 2016 | 2281 | 1.410 |
Why?
|
| Benzaldehydes | 14 | 2021 | 58 | 1.410 |
Why?
|
| American Heart Association | 26 | 2018 | 1055 | 1.380 |
Why?
|
| Blood Platelets | 23 | 2018 | 2506 | 1.360 |
Why?
|
| C-Reactive Protein | 42 | 2018 | 3766 | 1.360 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 7 | 2013 | 320 | 1.350 |
Why?
|
| Risk Factors | 204 | 2024 | 72145 | 1.340 |
Why?
|
| Thromboembolism | 9 | 2020 | 983 | 1.320 |
Why?
|
| Antibodies, Monoclonal | 25 | 2023 | 9274 | 1.280 |
Why?
|
| Tyrosine | 25 | 2016 | 1460 | 1.270 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 11 | 2022 | 292 | 1.260 |
Why?
|
| Stents | 31 | 2021 | 3276 | 1.230 |
Why?
|
| Hospitalization | 64 | 2023 | 10232 | 1.190 |
Why?
|
| Cholesterol, HDL | 18 | 2022 | 1813 | 1.170 |
Why?
|
| Osteoarthritis | 8 | 2011 | 1034 | 1.160 |
Why?
|
| Tissue Plasminogen Activator | 37 | 2017 | 1262 | 1.160 |
Why?
|
| Cardiology | 15 | 2020 | 1658 | 1.160 |
Why?
|
| Myocardial Ischemia | 26 | 2018 | 2145 | 1.160 |
Why?
|
| Coronary Thrombosis | 17 | 2018 | 494 | 1.140 |
Why?
|
| Hypoglycemic Agents | 29 | 2023 | 2866 | 1.140 |
Why?
|
| Pyrazoles | 8 | 2017 | 1970 | 1.140 |
Why?
|
| Dose-Response Relationship, Drug | 63 | 2020 | 10943 | 1.120 |
Why?
|
| Angina Pectoris | 16 | 2010 | 977 | 1.100 |
Why?
|
| Clinical Trials as Topic | 62 | 2018 | 7901 | 1.070 |
Why?
|
| Natriuretic Peptide, Brain | 29 | 2023 | 1573 | 1.060 |
Why?
|
| Purinergic P2 Receptor Antagonists | 7 | 2010 | 71 | 1.050 |
Why?
|
| Cyclooxygenase Inhibitors | 6 | 2009 | 371 | 1.020 |
Why?
|
| Adrenergic beta-Antagonists | 20 | 2023 | 1239 | 1.020 |
Why?
|
| Syndrome | 54 | 2021 | 3248 | 1.020 |
Why?
|
| Lipids | 15 | 2023 | 3302 | 1.020 |
Why?
|
| Medication Adherence | 16 | 2022 | 2055 | 1.010 |
Why?
|
| Receptor, Cannabinoid, CB1 | 6 | 2008 | 143 | 0.980 |
Why?
|
| Diabetic Cardiomyopathies | 4 | 2018 | 96 | 0.980 |
Why?
|
| Diabetic Nephropathies | 9 | 2023 | 983 | 0.980 |
Why?
|
| Cardiovascular System | 6 | 2021 | 827 | 0.960 |
Why?
|
| Coronary Angiography | 76 | 2017 | 4567 | 0.940 |
Why?
|
| Time Factors | 123 | 2021 | 40054 | 0.930 |
Why?
|
| Drug-Eluting Stents | 10 | 2020 | 753 | 0.930 |
Why?
|
| Troponin I | 21 | 2020 | 619 | 0.920 |
Why?
|
| Receptors, Purinergic P2Y12 | 8 | 2016 | 132 | 0.910 |
Why?
|
| Administration, Oral | 33 | 2021 | 3913 | 0.900 |
Why?
|
| Diabetic Angiopathies | 14 | 2019 | 820 | 0.890 |
Why?
|
| Primary Prevention | 9 | 2021 | 1166 | 0.890 |
Why?
|
| Peptide Fragments | 23 | 2023 | 5095 | 0.880 |
Why?
|
| Glomerular Filtration Rate | 20 | 2022 | 2167 | 0.880 |
Why?
|
| United States | 130 | 2023 | 69693 | 0.870 |
Why?
|
| Pyrrolidines | 20 | 2010 | 342 | 0.860 |
Why?
|
| Acute Disease | 66 | 2012 | 7141 | 0.850 |
Why?
|
| Hypertension | 24 | 2023 | 8455 | 0.850 |
Why?
|
| Troponin T | 16 | 2022 | 749 | 0.850 |
Why?
|
| Arthritis | 5 | 2011 | 658 | 0.830 |
Why?
|
| Influenza Vaccines | 5 | 2022 | 733 | 0.830 |
Why?
|
| Proprotein Convertases | 3 | 2023 | 95 | 0.830 |
Why?
|
| Coronary Circulation | 30 | 2014 | 1572 | 0.820 |
Why?
|
| Lipoprotein(a) | 5 | 2024 | 425 | 0.820 |
Why?
|
| Drug Administration Schedule | 25 | 2021 | 4929 | 0.820 |
Why?
|
| Quality of Health Care | 21 | 2015 | 4369 | 0.810 |
Why?
|
| Research Design | 21 | 2018 | 5979 | 0.800 |
Why?
|
| Growth Differentiation Factor 15 | 9 | 2023 | 176 | 0.790 |
Why?
|
| Proportional Hazards Models | 48 | 2021 | 12344 | 0.780 |
Why?
|
| Proton Pump Inhibitors | 8 | 2020 | 521 | 0.780 |
Why?
|
| Troponin | 10 | 2011 | 524 | 0.780 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 16 | 2023 | 1517 | 0.760 |
Why?
|
| Benzimidazoles | 4 | 2020 | 848 | 0.760 |
Why?
|
| Pyridones | 2 | 2017 | 712 | 0.750 |
Why?
|
| Evidence-Based Medicine | 29 | 2020 | 3611 | 0.750 |
Why?
|
| Blood Coagulation | 9 | 2020 | 1126 | 0.750 |
Why?
|
| Platelet Aggregation | 11 | 2012 | 800 | 0.730 |
Why?
|
| Chlamydophila Infections | 3 | 2005 | 23 | 0.720 |
Why?
|
| Follow-Up Studies | 90 | 2021 | 39004 | 0.720 |
Why?
|
| Diabetes Mellitus | 20 | 2023 | 5724 | 0.720 |
Why?
|
| Albuminuria | 5 | 2022 | 683 | 0.710 |
Why?
|
| Drug Costs | 7 | 2020 | 1104 | 0.710 |
Why?
|
| Graft Occlusion, Vascular | 4 | 2021 | 548 | 0.710 |
Why?
|
| Hypertriglyceridemia | 1 | 2023 | 293 | 0.700 |
Why?
|
| Bone Neoplasms | 11 | 2014 | 2522 | 0.700 |
Why?
|
| Cardiovascular Agents | 12 | 2019 | 848 | 0.700 |
Why?
|
| Quality Assurance, Health Care | 15 | 2013 | 2211 | 0.700 |
Why?
|
| Antihypertensive Agents | 11 | 2018 | 2043 | 0.690 |
Why?
|
| Hospital Mortality | 40 | 2017 | 5310 | 0.680 |
Why?
|
| Gastrointestinal Hemorrhage | 9 | 2016 | 1130 | 0.680 |
Why?
|
| Thrombin | 6 | 2011 | 598 | 0.680 |
Why?
|
| Hirudins | 7 | 2010 | 182 | 0.670 |
Why?
|
| Renal Insufficiency | 7 | 2023 | 802 | 0.660 |
Why?
|
| Survival Rate | 58 | 2020 | 12773 | 0.660 |
Why?
|
| Drug Tolerance | 2 | 2019 | 375 | 0.660 |
Why?
|
| Survival Analysis | 44 | 2021 | 10248 | 0.660 |
Why?
|
| Point-of-Care Systems | 6 | 2015 | 1175 | 0.650 |
Why?
|
| Influenza, Human | 5 | 2022 | 1472 | 0.640 |
Why?
|
| Prognosis | 77 | 2023 | 29010 | 0.640 |
Why?
|
| Hospitals | 16 | 2016 | 3937 | 0.640 |
Why?
|
| Prospective Studies | 79 | 2023 | 53187 | 0.630 |
Why?
|
| Blood Pressure | 11 | 2023 | 8541 | 0.620 |
Why?
|
| Risk | 31 | 2020 | 9679 | 0.600 |
Why?
|
| Drug Resistance | 10 | 2017 | 1608 | 0.600 |
Why?
|
| Object Attachment | 1 | 2020 | 313 | 0.600 |
Why?
|
| Incidence | 48 | 2021 | 20928 | 0.600 |
Why?
|
| Immunoglobulin Fab Fragments | 13 | 2016 | 482 | 0.580 |
Why?
|
| Chlamydophila pneumoniae | 4 | 2005 | 55 | 0.570 |
Why?
|
| Patient Care | 3 | 2013 | 639 | 0.570 |
Why?
|
| Recurrence | 48 | 2020 | 8333 | 0.570 |
Why?
|
| Multivariate Analysis | 46 | 2017 | 12242 | 0.560 |
Why?
|
| Glycosides | 3 | 2021 | 107 | 0.560 |
Why?
|
| Alanine | 20 | 2010 | 572 | 0.550 |
Why?
|
| Blood Pressure Determination | 3 | 2018 | 632 | 0.550 |
Why?
|
| Patient Selection | 21 | 2020 | 4214 | 0.550 |
Why?
|
| Lipid Metabolism | 5 | 2020 | 1887 | 0.550 |
Why?
|
| Gastrointestinal Diseases | 5 | 2013 | 1167 | 0.540 |
Why?
|
| Thiophenes | 4 | 2013 | 590 | 0.540 |
Why?
|
| Apolipoprotein B-100 | 2 | 2016 | 148 | 0.540 |
Why?
|
| Education, Medical, Continuing | 6 | 2017 | 839 | 0.530 |
Why?
|
| Kidney | 16 | 2023 | 7167 | 0.520 |
Why?
|
| Aged, 80 and over | 73 | 2023 | 57683 | 0.520 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 4 | 2013 | 453 | 0.520 |
Why?
|
| Lomustine | 1 | 2015 | 59 | 0.520 |
Why?
|
| Endocannabinoids | 2 | 2007 | 116 | 0.520 |
Why?
|
| Kaplan-Meier Estimate | 31 | 2020 | 6534 | 0.520 |
Why?
|
| Arteriosclerosis | 4 | 2015 | 1092 | 0.520 |
Why?
|
| Societies, Medical | 14 | 2020 | 3740 | 0.510 |
Why?
|
| Protease Inhibitors | 1 | 2019 | 790 | 0.510 |
Why?
|
| Vascular Patency | 15 | 2010 | 885 | 0.500 |
Why?
|
| Histiocytic Sarcoma | 1 | 2015 | 44 | 0.500 |
Why?
|
| Metformin | 4 | 2023 | 829 | 0.490 |
Why?
|
| Dog Diseases | 1 | 2015 | 136 | 0.490 |
Why?
|
| Multicenter Studies as Topic | 16 | 2022 | 1661 | 0.490 |
Why?
|
| Diabetes Complications | 4 | 2018 | 1359 | 0.480 |
Why?
|
| beta-Alanine | 2 | 2011 | 74 | 0.480 |
Why?
|
| Fluoroquinolones | 7 | 2007 | 308 | 0.470 |
Why?
|
| Brain Ischemia | 4 | 2022 | 3258 | 0.460 |
Why?
|
| Triglycerides | 6 | 2015 | 2450 | 0.460 |
Why?
|
| Arthritis, Rheumatoid | 6 | 2011 | 3695 | 0.460 |
Why?
|
| Odds Ratio | 36 | 2019 | 9846 | 0.450 |
Why?
|
| Language | 2 | 2012 | 1458 | 0.450 |
Why?
|
| Partial Thromboplastin Time | 8 | 2010 | 206 | 0.450 |
Why?
|
| Fenofibrate | 2 | 2016 | 88 | 0.440 |
Why?
|
| Platelet Activation | 8 | 2016 | 671 | 0.440 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2011 | 257 | 0.440 |
Why?
|
| Heparin, Low-Molecular-Weight | 9 | 2011 | 339 | 0.440 |
Why?
|
| Lipoproteins | 1 | 2017 | 876 | 0.430 |
Why?
|
| Risk Reduction Behavior | 9 | 2020 | 1123 | 0.430 |
Why?
|
| Emergency Medical Services | 10 | 2009 | 1914 | 0.420 |
Why?
|
| Combined Modality Therapy | 19 | 2020 | 8621 | 0.420 |
Why?
|
| Age Factors | 43 | 2021 | 18355 | 0.420 |
Why?
|
| Cause of Death | 12 | 2021 | 3571 | 0.420 |
Why?
|
| Sex Factors | 29 | 2021 | 10392 | 0.420 |
Why?
|
| Obesity | 12 | 2013 | 12705 | 0.410 |
Why?
|
| Retrospective Studies | 73 | 2024 | 77098 | 0.410 |
Why?
|
| Cost Sharing | 4 | 2020 | 407 | 0.410 |
Why?
|
| Medication Errors | 4 | 2002 | 797 | 0.410 |
Why?
|
| Safety | 7 | 2019 | 1185 | 0.410 |
Why?
|
| Fasting | 1 | 2017 | 1589 | 0.400 |
Why?
|
| Coronary Restenosis | 3 | 2010 | 424 | 0.400 |
Why?
|
| Length of Stay | 12 | 2022 | 6294 | 0.400 |
Why?
|
| Patient Care Planning | 5 | 2019 | 921 | 0.390 |
Why?
|
| Kidney Diseases | 8 | 2023 | 2145 | 0.390 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2011 | 29 | 0.390 |
Why?
|
| Clinical Trials, Phase III as Topic | 6 | 2019 | 839 | 0.390 |
Why?
|
| Patient Discharge | 14 | 2014 | 3300 | 0.380 |
Why?
|
| Omeprazole | 4 | 2016 | 112 | 0.380 |
Why?
|
| Blood Glucose | 8 | 2018 | 6249 | 0.380 |
Why?
|
| Quality Improvement | 13 | 2020 | 3738 | 0.380 |
Why?
|
| Niacin | 2 | 2010 | 116 | 0.380 |
Why?
|
| Premedication | 3 | 2007 | 257 | 0.380 |
Why?
|
| Inpatients | 5 | 2015 | 2495 | 0.380 |
Why?
|
| Enoxaparin | 7 | 2006 | 377 | 0.370 |
Why?
|
| Daptomycin | 1 | 2011 | 73 | 0.370 |
Why?
|
| Mortality | 9 | 2021 | 2857 | 0.370 |
Why?
|
| Hyperlipoproteinemia Type II | 3 | 2020 | 373 | 0.370 |
Why?
|
| Cost-Benefit Analysis | 12 | 2020 | 5385 | 0.370 |
Why?
|
| Heart Conduction System | 8 | 2009 | 1048 | 0.360 |
Why?
|
| Disease Management | 10 | 2021 | 2450 | 0.360 |
Why?
|
| Kidney Failure, Chronic | 6 | 2023 | 2536 | 0.350 |
Why?
|
| United States Food and Drug Administration | 7 | 2020 | 1581 | 0.350 |
Why?
|
| Angiotensin Receptor Antagonists | 8 | 2023 | 923 | 0.350 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 611 | 0.350 |
Why?
|
| Terminology as Topic | 4 | 2012 | 1548 | 0.350 |
Why?
|
| Humerus | 2 | 2009 | 265 | 0.340 |
Why?
|
| Morpholines | 1 | 2012 | 561 | 0.340 |
Why?
|
| Stroke Volume | 14 | 2023 | 4983 | 0.340 |
Why?
|
| Glucosides | 3 | 2019 | 446 | 0.340 |
Why?
|
| Cohort Studies | 34 | 2023 | 40450 | 0.340 |
Why?
|
| Severity of Illness Index | 33 | 2019 | 15530 | 0.330 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 5 | 2016 | 127 | 0.330 |
Why?
|
| Predictive Value of Tests | 36 | 2021 | 15056 | 0.330 |
Why?
|
| Oligonucleotides | 1 | 2012 | 572 | 0.330 |
Why?
|
| Cystatin C | 3 | 2018 | 250 | 0.330 |
Why?
|
| Inflammation | 7 | 2017 | 10578 | 0.330 |
Why?
|
| Anti-Ulcer Agents | 1 | 2009 | 119 | 0.330 |
Why?
|
| Plasminogen Activators | 10 | 2004 | 209 | 0.320 |
Why?
|
| Hyperglycemia | 5 | 2017 | 1368 | 0.320 |
Why?
|
| Doxorubicin | 1 | 2015 | 2215 | 0.320 |
Why?
|
| Prostheses and Implants | 3 | 2009 | 1385 | 0.320 |
Why?
|
| Adult | 99 | 2023 | 213712 | 0.320 |
Why?
|
| Vision Disorders | 1 | 2015 | 1057 | 0.320 |
Why?
|
| Chi-Square Distribution | 19 | 2018 | 3510 | 0.320 |
Why?
|
| Hirudin Therapy | 8 | 1997 | 43 | 0.320 |
Why?
|
| Coronary Care Units | 3 | 2005 | 214 | 0.320 |
Why?
|
| Anti-Bacterial Agents | 5 | 2011 | 7153 | 0.320 |
Why?
|
| Comorbidity | 19 | 2021 | 10372 | 0.310 |
Why?
|
| Creatine Kinase, MB Form | 9 | 2014 | 214 | 0.310 |
Why?
|
| Hyperlipidemias | 5 | 2017 | 786 | 0.310 |
Why?
|
| Interleukin-6 | 5 | 2021 | 3199 | 0.310 |
Why?
|
| Creatinine | 11 | 2023 | 1916 | 0.310 |
Why?
|
| Postoperative Hemorrhage | 3 | 2015 | 409 | 0.300 |
Why?
|
| Health Expenditures | 5 | 2022 | 2346 | 0.300 |
Why?
|
| Ventricular Dysfunction, Left | 9 | 2019 | 2059 | 0.300 |
Why?
|
| CD40 Ligand | 5 | 2017 | 526 | 0.300 |
Why?
|
| Logistic Models | 30 | 2019 | 13403 | 0.300 |
Why?
|
| Smoking | 15 | 2016 | 8969 | 0.290 |
Why?
|
| Algorithms | 9 | 2020 | 13853 | 0.290 |
Why?
|
| Drug Substitution | 2 | 2019 | 281 | 0.290 |
Why?
|
| Benzhydryl Compounds | 3 | 2019 | 840 | 0.290 |
Why?
|
| Emergency Service, Hospital | 15 | 2012 | 7645 | 0.290 |
Why?
|
| Leukocyte Count | 5 | 2008 | 1583 | 0.280 |
Why?
|
| Chest Pain | 4 | 2005 | 1113 | 0.280 |
Why?
|
| Europe | 7 | 2019 | 3339 | 0.280 |
Why?
|
| Hypoglycemia | 4 | 2023 | 859 | 0.270 |
Why?
|
| Meta-Analysis as Topic | 6 | 2021 | 1342 | 0.270 |
Why?
|
| Lipoproteins, HDL | 1 | 2010 | 637 | 0.270 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2012 | 1504 | 0.270 |
Why?
|
| Benzodiazepines | 1 | 2011 | 1101 | 0.260 |
Why?
|
| Intracranial Hemorrhages | 8 | 2008 | 854 | 0.260 |
Why?
|
| Lovastatin | 1 | 2005 | 120 | 0.260 |
Why?
|
| Endothelium, Vascular | 4 | 2010 | 4455 | 0.260 |
Why?
|
| Down-Regulation | 4 | 2021 | 3001 | 0.250 |
Why?
|
| Atrial Natriuretic Factor | 6 | 2016 | 393 | 0.250 |
Why?
|
| Drug Utilization | 10 | 2019 | 1181 | 0.250 |
Why?
|
| Arthroplasty, Replacement | 1 | 2009 | 336 | 0.250 |
Why?
|
| Coronary Vessels | 11 | 2021 | 3099 | 0.250 |
Why?
|
| Smoking Cessation | 8 | 2014 | 2068 | 0.240 |
Why?
|
| Peripheral Arterial Disease | 3 | 2022 | 1184 | 0.240 |
Why?
|
| Arthroplasty | 1 | 2007 | 305 | 0.240 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2008 | 501 | 0.240 |
Why?
|
| Catheter Ablation | 1 | 2017 | 2746 | 0.240 |
Why?
|
| Prosthesis Failure | 2 | 2007 | 1203 | 0.240 |
Why?
|
| Heart Diseases | 4 | 2010 | 2789 | 0.240 |
Why?
|
| Venous Thromboembolism | 2 | 2020 | 1668 | 0.240 |
Why?
|
| Brachial Artery | 1 | 2005 | 370 | 0.230 |
Why?
|
| Injections, Subcutaneous | 5 | 2017 | 664 | 0.230 |
Why?
|
| Drug Labeling | 2 | 2018 | 231 | 0.230 |
Why?
|
| Blood Chemical Analysis | 2 | 2018 | 440 | 0.230 |
Why?
|
| Dyspnea | 5 | 2023 | 1298 | 0.230 |
Why?
|
| Peripheral Vascular Diseases | 4 | 2009 | 550 | 0.230 |
Why?
|
| Subtilisin | 1 | 2023 | 12 | 0.230 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2010 | 1788 | 0.230 |
Why?
|
| Renal Dialysis | 2 | 2023 | 1780 | 0.230 |
Why?
|
| Ischemic Attack, Transient | 4 | 2012 | 934 | 0.230 |
Why?
|
| Reference Values | 11 | 2018 | 4982 | 0.230 |
Why?
|
| Standard of Care | 5 | 2023 | 562 | 0.230 |
Why?
|
| Arteriolosclerosis | 1 | 2023 | 19 | 0.220 |
Why?
|
| Monte Carlo Method | 2 | 2019 | 1254 | 0.220 |
Why?
|
| Acetabulum | 1 | 2007 | 525 | 0.220 |
Why?
|
| Range of Motion, Articular | 2 | 2009 | 1577 | 0.220 |
Why?
|
| Creatine Kinase | 10 | 2004 | 694 | 0.220 |
Why?
|
| Glycosuria | 1 | 2022 | 43 | 0.210 |
Why?
|
| Polymorphism, Genetic | 9 | 2011 | 4328 | 0.210 |
Why?
|
| Cholesterol | 8 | 2021 | 2895 | 0.210 |
Why?
|
| Bone Nails | 1 | 2003 | 219 | 0.210 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2006 | 1155 | 0.210 |
Why?
|
| Hospital Costs | 4 | 2017 | 980 | 0.210 |
Why?
|
| Shoulder Joint | 1 | 2009 | 693 | 0.210 |
Why?
|
| Thiazolidinediones | 3 | 2010 | 476 | 0.210 |
Why?
|
| Body Weight | 7 | 2022 | 4664 | 0.210 |
Why?
|
| Computers, Handheld | 1 | 2004 | 208 | 0.200 |
Why?
|
| Liver Diseases | 2 | 2017 | 1252 | 0.200 |
Why?
|
| Lower Extremity | 2 | 2006 | 1151 | 0.200 |
Why?
|
| Disease Progression | 13 | 2021 | 13256 | 0.200 |
Why?
|
| Financial Support | 2 | 2020 | 115 | 0.200 |
Why?
|
| Anistreplase | 3 | 1997 | 12 | 0.200 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2004 | 277 | 0.200 |
Why?
|
| Ventricular Function, Left | 6 | 2023 | 3656 | 0.200 |
Why?
|
| Echinococcosis | 1 | 2001 | 30 | 0.200 |
Why?
|
| Endothelial Cells | 2 | 2012 | 3455 | 0.200 |
Why?
|
| Health Behavior | 3 | 2009 | 2630 | 0.200 |
Why?
|
| Atrial Flutter | 2 | 2022 | 264 | 0.200 |
Why?
|
| Myoglobin | 5 | 2002 | 160 | 0.190 |
Why?
|
| Lipoproteins, LDL | 5 | 2011 | 628 | 0.190 |
Why?
|
| Placebo Effect | 4 | 2019 | 502 | 0.190 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2021 | 68 | 0.190 |
Why?
|
| Healthcare Disparities | 6 | 2019 | 3151 | 0.190 |
Why?
|
| Sarcoma | 3 | 2007 | 1895 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2023 | 3336 | 0.190 |
Why?
|
| Anti-Obesity Agents | 3 | 2009 | 215 | 0.190 |
Why?
|
| Femur | 1 | 2007 | 1297 | 0.190 |
Why?
|
| Overweight | 2 | 2009 | 2366 | 0.190 |
Why?
|
| American Medical Association | 2 | 2011 | 65 | 0.190 |
Why?
|
| Drug Evaluation | 2 | 2015 | 637 | 0.190 |
Why?
|
| Emergency Medicine | 1 | 2010 | 1205 | 0.190 |
Why?
|
| Self Report | 4 | 2020 | 3548 | 0.180 |
Why?
|
| Recombinant Proteins | 13 | 2017 | 6608 | 0.180 |
Why?
|
| Placebos | 3 | 2020 | 1677 | 0.180 |
Why?
|
| Tetrazoles | 2 | 2019 | 835 | 0.180 |
Why?
|
| Fibrinolysis | 3 | 2011 | 322 | 0.180 |
Why?
|
| Forecasting | 6 | 2017 | 2948 | 0.180 |
Why?
|
| Neopterin | 2 | 2011 | 56 | 0.170 |
Why?
|
| Hospitals, Urban | 2 | 2013 | 499 | 0.170 |
Why?
|
| Analysis of Variance | 10 | 2018 | 6365 | 0.170 |
Why?
|
| Decision Support Techniques | 3 | 2018 | 1952 | 0.170 |
Why?
|
| Soft Tissue Infections | 1 | 2001 | 155 | 0.170 |
Why?
|
| Sex Characteristics | 3 | 2019 | 2585 | 0.170 |
Why?
|
| Advisory Committees | 2 | 2014 | 773 | 0.170 |
Why?
|
| Drug Prescriptions | 6 | 2018 | 1636 | 0.170 |
Why?
|
| Clinical Protocols | 4 | 2016 | 1459 | 0.170 |
Why?
|
| Attitude of Health Personnel | 4 | 2021 | 3839 | 0.170 |
Why?
|
| Triage | 2 | 2005 | 977 | 0.170 |
Why?
|
| Confidence Intervals | 9 | 2016 | 2970 | 0.170 |
Why?
|
| Heart Rate | 6 | 2019 | 4091 | 0.160 |
Why?
|
| Economics, Medical | 1 | 1999 | 113 | 0.160 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2023 | 582 | 0.160 |
Why?
|
| Clinical Medicine | 3 | 2004 | 147 | 0.160 |
Why?
|
| Nursing, Private Duty | 1 | 1998 | 4 | 0.160 |
Why?
|
| Peroxidase | 3 | 2016 | 610 | 0.160 |
Why?
|
| Tachycardia, Ventricular | 3 | 2016 | 1272 | 0.160 |
Why?
|
| Adiponectin | 2 | 2017 | 1099 | 0.160 |
Why?
|
| France | 1 | 2019 | 517 | 0.160 |
Why?
|
| Galectin 3 | 3 | 2020 | 227 | 0.160 |
Why?
|
| Apolipoprotein A-I | 2 | 2010 | 280 | 0.160 |
Why?
|
| Diabetic Retinopathy | 1 | 2007 | 1205 | 0.160 |
Why?
|
| Muscular Diseases | 2 | 2020 | 557 | 0.160 |
Why?
|
| Staff Development | 2 | 2011 | 223 | 0.160 |
Why?
|
| Interleukin-18 | 1 | 2019 | 248 | 0.160 |
Why?
|
| Interleukin-13 Receptor alpha1 Subunit | 1 | 2017 | 24 | 0.160 |
Why?
|
| Pharmacology | 1 | 1998 | 103 | 0.160 |
Why?
|
| Piperazines | 3 | 2013 | 2488 | 0.160 |
Why?
|
| Prevalence | 10 | 2022 | 15194 | 0.160 |
Why?
|
| Anti-Infective Agents | 4 | 2007 | 971 | 0.150 |
Why?
|
| Databases, Factual | 4 | 2021 | 7716 | 0.150 |
Why?
|
| Education, Nursing, Continuing | 1 | 1998 | 75 | 0.150 |
Why?
|
| Peptides | 7 | 2016 | 4392 | 0.150 |
Why?
|
| Drug Therapy | 1 | 2021 | 497 | 0.150 |
Why?
|
| Clinical Competence | 3 | 2012 | 4681 | 0.150 |
Why?
|
| Health Care Surveys | 5 | 2014 | 2451 | 0.150 |
Why?
|
| Probability | 7 | 2010 | 2502 | 0.150 |
Why?
|
| Treatment Failure | 5 | 2014 | 2615 | 0.150 |
Why?
|
| Vascular Diseases | 2 | 2018 | 1155 | 0.150 |
Why?
|
| Sodium-Glucose Transporter 2 | 3 | 2023 | 85 | 0.150 |
Why?
|
| Insurance, Health | 4 | 2021 | 2493 | 0.150 |
Why?
|
| Dyspepsia | 2 | 2016 | 114 | 0.150 |
Why?
|
| Platelet Count | 5 | 2017 | 780 | 0.150 |
Why?
|
| Protein Precursors | 5 | 2018 | 1154 | 0.150 |
Why?
|
| Deductibles and Coinsurance | 1 | 2020 | 316 | 0.150 |
Why?
|
| Endpoint Determination | 5 | 2013 | 600 | 0.150 |
Why?
|
| Insulin Infusion Systems | 1 | 1999 | 212 | 0.150 |
Why?
|
| Colorimetry | 1 | 2017 | 147 | 0.150 |
Why?
|
| Health Personnel | 1 | 2011 | 3210 | 0.150 |
Why?
|
| Critical Care | 3 | 2011 | 2640 | 0.150 |
Why?
|
| Monitoring, Physiologic | 1 | 2005 | 1737 | 0.150 |
Why?
|
| Eligibility Determination | 2 | 2017 | 403 | 0.150 |
Why?
|
| Acute Kidney Injury | 3 | 2020 | 1967 | 0.150 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2022 | 1808 | 0.150 |
Why?
|
| Models, Biological | 1 | 2013 | 9581 | 0.140 |
Why?
|
| Exercise Test | 4 | 2014 | 2075 | 0.140 |
Why?
|
| Fractures, Bone | 2 | 2006 | 1945 | 0.140 |
Why?
|
| Cardiotonic Agents | 2 | 2014 | 535 | 0.140 |
Why?
|
| Fatty Liver | 1 | 2022 | 728 | 0.140 |
Why?
|
| Sulfonylurea Compounds | 1 | 2018 | 204 | 0.140 |
Why?
|
| Blood Proteins | 3 | 2020 | 1122 | 0.140 |
Why?
|
| Health Status | 2 | 2017 | 4030 | 0.140 |
Why?
|
| Patient Admission | 4 | 2019 | 1380 | 0.140 |
Why?
|
| Death, Sudden, Cardiac | 4 | 2022 | 1541 | 0.140 |
Why?
|
| Consensus | 3 | 2020 | 2935 | 0.140 |
Why?
|
| Drug Approval | 2 | 2014 | 740 | 0.140 |
Why?
|
| Preoperative Care | 3 | 2011 | 2245 | 0.140 |
Why?
|
| Glucose | 4 | 2023 | 4391 | 0.130 |
Why?
|
| Ventricular Fibrillation | 2 | 2009 | 538 | 0.130 |
Why?
|
| Quality Indicators, Health Care | 6 | 2020 | 1831 | 0.130 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2019 | 395 | 0.130 |
Why?
|
| Case-Control Studies | 11 | 2019 | 21719 | 0.130 |
Why?
|
| Limb Salvage | 2 | 2009 | 433 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2021 | 3915 | 0.130 |
Why?
|
| Patient Transfer | 1 | 2002 | 760 | 0.130 |
Why?
|
| Program Evaluation | 3 | 2014 | 2485 | 0.130 |
Why?
|
| Research Personnel | 3 | 2004 | 573 | 0.130 |
Why?
|
| Vitamin K | 1 | 2017 | 294 | 0.130 |
Why?
|
| Drug Synergism | 3 | 2016 | 1791 | 0.130 |
Why?
|
| Immunoassay | 4 | 2010 | 752 | 0.130 |
Why?
|
| Drug Monitoring | 4 | 2016 | 956 | 0.130 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 1 | 2017 | 222 | 0.130 |
Why?
|
| Area Under Curve | 4 | 2015 | 1653 | 0.130 |
Why?
|
| Blood Flow Velocity | 7 | 2005 | 1423 | 0.130 |
Why?
|
| Circadian Rhythm | 3 | 2013 | 2623 | 0.120 |
Why?
|
| Computer-Assisted Instruction | 1 | 1998 | 365 | 0.120 |
Why?
|
| Physical Exertion | 1 | 2017 | 695 | 0.120 |
Why?
|
| Resistin | 1 | 2015 | 170 | 0.120 |
Why?
|
| Outpatients | 3 | 2013 | 1483 | 0.120 |
Why?
|
| Isoenzymes | 8 | 2004 | 1725 | 0.120 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 1994 | 50 | 0.120 |
Why?
|
| Statistics, Nonparametric | 7 | 2009 | 2885 | 0.120 |
Why?
|
| Atrioventricular Block | 1 | 2015 | 120 | 0.120 |
Why?
|
| Echocardiography, Stress | 1 | 2014 | 131 | 0.120 |
Why?
|
| Postoperative Care | 4 | 2020 | 1484 | 0.120 |
Why?
|
| Adolescent | 21 | 2021 | 85649 | 0.120 |
Why?
|
| False Positive Reactions | 3 | 2011 | 981 | 0.120 |
Why?
|
| Models, Economic | 1 | 2018 | 713 | 0.120 |
Why?
|
| Exercise | 4 | 2017 | 5611 | 0.120 |
Why?
|
| Natriuresis | 3 | 2022 | 124 | 0.110 |
Why?
|
| Models, Organizational | 2 | 2008 | 574 | 0.110 |
Why?
|
| Drug Combinations | 4 | 2019 | 1961 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2020 | 1434 | 0.110 |
Why?
|
| Diuretics | 3 | 2021 | 591 | 0.110 |
Why?
|
| Sleep | 2 | 2020 | 4604 | 0.110 |
Why?
|
| Serine Endopeptidases | 2 | 2015 | 1073 | 0.110 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2015 | 433 | 0.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 1820 | 0.110 |
Why?
|
| Foundations | 1 | 2013 | 94 | 0.110 |
Why?
|
| Nutrition Surveys | 2 | 2017 | 1656 | 0.110 |
Why?
|
| Pilot Projects | 7 | 2015 | 8297 | 0.110 |
Why?
|
| HIV | 1 | 2020 | 1600 | 0.110 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 891 | 0.110 |
Why?
|
| Curettage | 2 | 2014 | 73 | 0.110 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2018 | 2267 | 0.110 |
Why?
|
| Fibroblast Growth Factors | 1 | 2018 | 879 | 0.100 |
Why?
|
| Data Collection | 1 | 2001 | 3339 | 0.100 |
Why?
|
| Benzamidines | 2 | 2002 | 25 | 0.100 |
Why?
|
| ROC Curve | 5 | 2015 | 3528 | 0.100 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2020 | 941 | 0.100 |
Why?
|
| Inflammation Mediators | 2 | 2017 | 1889 | 0.100 |
Why?
|
| Epidemiologic Methods | 4 | 2010 | 1364 | 0.100 |
Why?
|
| Renin-Angiotensin System | 2 | 2014 | 759 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 13655 | 0.100 |
Why?
|
| Biopharmaceutics | 1 | 2011 | 22 | 0.100 |
Why?
|
| Databases as Topic | 1 | 2013 | 475 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 4 | 2013 | 2714 | 0.100 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 3 | 2023 | 236 | 0.100 |
Why?
|
| Biomedical Research | 2 | 2020 | 3306 | 0.100 |
Why?
|
| Ischemia | 2 | 2018 | 1911 | 0.100 |
Why?
|
| Epoprostenol | 1 | 2012 | 254 | 0.100 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 229 | 0.100 |
Why?
|
| Thrombocytopenia | 3 | 2006 | 1171 | 0.100 |
Why?
|
| Drug Interactions | 3 | 2010 | 1458 | 0.100 |
Why?
|
| Therapeutic Equivalency | 1 | 2011 | 145 | 0.100 |
Why?
|
| Propensity Score | 3 | 2017 | 1771 | 0.100 |
Why?
|
| Stockings, Compression | 1 | 2011 | 37 | 0.100 |
Why?
|
| Young Adult | 14 | 2021 | 56350 | 0.100 |
Why?
|
| Patient Readmission | 3 | 2017 | 3111 | 0.100 |
Why?
|
| Osteotomy | 2 | 2014 | 823 | 0.100 |
Why?
|
| Cineangiography | 4 | 1999 | 124 | 0.100 |
Why?
|
| Hernia, Hiatal | 1 | 2012 | 79 | 0.100 |
Why?
|
| Time | 2 | 2010 | 530 | 0.100 |
Why?
|
| Drug Dosage Calculations | 1 | 2011 | 113 | 0.100 |
Why?
|
| Reoperation | 5 | 2014 | 4200 | 0.090 |
Why?
|
| Diagnosis, Differential | 6 | 2011 | 12958 | 0.090 |
Why?
|
| Acetyl-CoA C-Acetyltransferase | 1 | 2010 | 8 | 0.090 |
Why?
|
| Ambulatory Care | 2 | 2013 | 2706 | 0.090 |
Why?
|
| Sodium-Glucose Transporter 1 | 2 | 2020 | 112 | 0.090 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2010 | 48 | 0.090 |
Why?
|
| Accreditation | 1 | 2013 | 449 | 0.090 |
Why?
|
| Dogs | 1 | 2015 | 3910 | 0.090 |
Why?
|
| Cerebrovascular Disorders | 3 | 2009 | 1499 | 0.090 |
Why?
|
| Sample Size | 3 | 2009 | 844 | 0.090 |
Why?
|
| Half-Life | 1 | 2011 | 658 | 0.090 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2010 | 93 | 0.090 |
Why?
|
| Health Surveys | 2 | 2011 | 4030 | 0.090 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 1712 | 0.090 |
Why?
|
| Fumarates | 1 | 2010 | 132 | 0.090 |
Why?
|
| Research Report | 1 | 2013 | 355 | 0.090 |
Why?
|
| Postoperative Complications | 6 | 2015 | 15244 | 0.090 |
Why?
|
| Insulin Resistance | 3 | 2008 | 3861 | 0.090 |
Why?
|
| Bradycardia | 1 | 2011 | 305 | 0.090 |
Why?
|
| Chronic Disease | 5 | 2017 | 9144 | 0.090 |
Why?
|
| Safety Management | 2 | 2008 | 782 | 0.090 |
Why?
|
| Time and Motion Studies | 1 | 2009 | 149 | 0.090 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2017 | 1499 | 0.080 |
Why?
|
| Withholding Treatment | 1 | 2013 | 598 | 0.080 |
Why?
|
| Minnesota | 1 | 2009 | 343 | 0.080 |
Why?
|
| Streptokinase | 4 | 2017 | 188 | 0.080 |
Why?
|
| Integrin beta3 | 1 | 2009 | 122 | 0.080 |
Why?
|
| Hospital Planning | 1 | 2008 | 20 | 0.080 |
Why?
|
| Life Style | 3 | 2012 | 3824 | 0.080 |
Why?
|
| Animals | 15 | 2021 | 168561 | 0.080 |
Why?
|
| Sepsis | 2 | 2013 | 2589 | 0.080 |
Why?
|
| Bayes Theorem | 4 | 2010 | 2303 | 0.080 |
Why?
|
| Exocytosis | 3 | 1985 | 353 | 0.080 |
Why?
|
| Valine | 1 | 2010 | 413 | 0.080 |
Why?
|
| Observation | 1 | 2010 | 312 | 0.080 |
Why?
|
| Linear Models | 7 | 2016 | 5948 | 0.080 |
Why?
|
| Adenosine Diphosphate | 1 | 2009 | 425 | 0.080 |
Why?
|
| Appetite Depressants | 1 | 2009 | 110 | 0.080 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2009 | 152 | 0.080 |
Why?
|
| Diagnosis-Related Groups | 1 | 2010 | 454 | 0.080 |
Why?
|
| Hospital Charges | 1 | 2010 | 362 | 0.080 |
Why?
|
| Bioterrorism | 1 | 2009 | 143 | 0.080 |
Why?
|
| Physicians | 2 | 2021 | 4554 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2020 | 3584 | 0.080 |
Why?
|
| Drug Administration Routes | 1 | 2008 | 153 | 0.080 |
Why?
|
| Hospitals, Rural | 1 | 2009 | 172 | 0.080 |
Why?
|
| Ultrasonography, Interventional | 4 | 2010 | 1483 | 0.080 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 1864 | 0.080 |
Why?
|
| Blood Coagulation Tests | 2 | 2003 | 263 | 0.080 |
Why?
|
| Proton-Translocating ATPases | 2 | 1985 | 116 | 0.080 |
Why?
|
| Body Mass Index | 3 | 2021 | 12695 | 0.080 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2015 | 3038 | 0.080 |
Why?
|
| Vitamin B Complex | 1 | 2010 | 288 | 0.080 |
Why?
|
| Sinoatrial Node | 1 | 2007 | 101 | 0.080 |
Why?
|
| Glycemic Index | 1 | 2010 | 395 | 0.080 |
Why?
|
| Infusions, Intravenous | 7 | 2005 | 2271 | 0.080 |
Why?
|
| Amides | 1 | 2010 | 458 | 0.070 |
Why?
|
| Calgranulin A | 1 | 2007 | 79 | 0.070 |
Why?
|
| Health Planning Guidelines | 1 | 2008 | 163 | 0.070 |
Why?
|
| Tuberculosis, Osteoarticular | 1 | 2007 | 26 | 0.070 |
Why?
|
| Calgranulin B | 1 | 2007 | 84 | 0.070 |
Why?
|
| Cerebral Hemorrhage | 4 | 2009 | 2643 | 0.070 |
Why?
|
| After-Hours Care | 1 | 2008 | 102 | 0.070 |
Why?
|
| Receptors, Cannabinoid | 1 | 2007 | 44 | 0.070 |
Why?
|
| Apolipoproteins B | 1 | 2009 | 373 | 0.070 |
Why?
|
| Decision Making | 2 | 2013 | 3869 | 0.070 |
Why?
|
| Cardiac Output, Low | 2 | 2006 | 193 | 0.070 |
Why?
|
| Leptin | 1 | 2015 | 1593 | 0.070 |
Why?
|
| Patient Compliance | 3 | 2013 | 2680 | 0.070 |
Why?
|
| India | 2 | 2013 | 2187 | 0.070 |
Why?
|
| Hyperemia | 1 | 2008 | 224 | 0.070 |
Why?
|
| Vaccination | 2 | 2022 | 3256 | 0.070 |
Why?
|
| Sentinel Surveillance | 1 | 2008 | 281 | 0.070 |
Why?
|
| Cardiovascular Surgical Procedures | 2 | 2012 | 194 | 0.070 |
Why?
|
| Counseling | 2 | 2012 | 1521 | 0.070 |
Why?
|
| Longitudinal Studies | 7 | 2023 | 13921 | 0.070 |
Why?
|
| Forced Expiratory Volume | 1 | 2011 | 1741 | 0.070 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2007 | 469 | 0.070 |
Why?
|
| Emergency Treatment | 3 | 2012 | 517 | 0.070 |
Why?
|
| Periosteum | 1 | 2007 | 138 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2009 | 627 | 0.070 |
Why?
|
| Uric Acid | 2 | 2022 | 760 | 0.070 |
Why?
|
| Ambulances | 1 | 2006 | 95 | 0.070 |
Why?
|
| Genetic Engineering | 1 | 2012 | 952 | 0.070 |
Why?
|
| Regression Analysis | 9 | 2009 | 6452 | 0.070 |
Why?
|
| Health Services Accessibility | 4 | 2019 | 5133 | 0.070 |
Why?
|
| Injections, Intravenous | 4 | 2001 | 1420 | 0.070 |
Why?
|
| Office Visits | 1 | 2010 | 598 | 0.070 |
Why?
|
| Pneumonia | 2 | 2018 | 2117 | 0.070 |
Why?
|
| Amiodarone | 1 | 2007 | 212 | 0.070 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2005 | 21 | 0.070 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 6891 | 0.070 |
Why?
|
| Information Dissemination | 1 | 2014 | 1100 | 0.070 |
Why?
|
| Fluorobenzenes | 1 | 2007 | 184 | 0.070 |
Why?
|
| Awards and Prizes | 1 | 2010 | 375 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 3504 | 0.070 |
Why?
|
| Reproducibility of Results | 10 | 2008 | 19862 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 3014 | 0.070 |
Why?
|
| Fibrin | 1 | 2008 | 506 | 0.070 |
Why?
|
| Receptors, Cell Surface | 2 | 2008 | 2867 | 0.070 |
Why?
|
| Pulmonary Embolism | 2 | 2007 | 2370 | 0.070 |
Why?
|
| Education | 1 | 2009 | 543 | 0.070 |
Why?
|
| Physicians, Primary Care | 1 | 2012 | 577 | 0.070 |
Why?
|
| Europe, Eastern | 1 | 2005 | 75 | 0.070 |
Why?
|
| Phospholipases A | 1 | 2006 | 216 | 0.070 |
Why?
|
| Benchmarking | 2 | 2009 | 1038 | 0.070 |
Why?
|
| Galectins | 2 | 2020 | 267 | 0.070 |
Why?
|
| Heart Arrest | 1 | 2015 | 1469 | 0.070 |
Why?
|
| Biological Transport | 1 | 2010 | 2119 | 0.070 |
Why?
|
| Blood Urea Nitrogen | 1 | 2005 | 191 | 0.060 |
Why?
|
| Prosthesis Design | 2 | 2020 | 2110 | 0.060 |
Why?
|
| Endarterectomy, Carotid | 1 | 2010 | 546 | 0.060 |
Why?
|
| Shock, Septic | 1 | 2012 | 773 | 0.060 |
Why?
|
| Pelvic Bones | 1 | 2007 | 265 | 0.060 |
Why?
|
| Foreign-Body Migration | 1 | 2007 | 221 | 0.060 |
Why?
|
| Venous Thrombosis | 2 | 2011 | 1237 | 0.060 |
Why?
|
| Oxygen Consumption | 1 | 2011 | 1869 | 0.060 |
Why?
|
| Radiography | 4 | 2009 | 7010 | 0.060 |
Why?
|
| HIV Infections | 3 | 2020 | 16678 | 0.060 |
Why?
|
| Sulfonamides | 2 | 2020 | 1932 | 0.060 |
Why?
|
| Sex Distribution | 3 | 2018 | 2295 | 0.060 |
Why?
|
| Chondrosarcoma | 1 | 2007 | 309 | 0.060 |
Why?
|
| Decision Trees | 1 | 2006 | 506 | 0.060 |
Why?
|
| Appetite Regulation | 1 | 2005 | 88 | 0.060 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2006 | 301 | 0.060 |
Why?
|
| Behavior | 1 | 2007 | 560 | 0.060 |
Why?
|
| Iron | 1 | 2013 | 1773 | 0.060 |
Why?
|
| Chemokine CCL2 | 2 | 2007 | 617 | 0.060 |
Why?
|
| Angioplasty | 2 | 1999 | 364 | 0.060 |
Why?
|
| Bone Transplantation | 1 | 2009 | 907 | 0.060 |
Why?
|
| Apolipoproteins | 2 | 2012 | 315 | 0.060 |
Why?
|
| Embolism, Cholesterol | 1 | 2004 | 34 | 0.060 |
Why?
|
| Carbon Dioxide | 3 | 1985 | 1141 | 0.060 |
Why?
|
| North America | 2 | 2019 | 1249 | 0.060 |
Why?
|
| Endothelium | 1 | 2007 | 778 | 0.060 |
Why?
|
| Emergencies | 2 | 2009 | 1164 | 0.060 |
Why?
|
| Carotid Artery Diseases | 1 | 2010 | 882 | 0.060 |
Why?
|
| Coronary Stenosis | 3 | 2005 | 834 | 0.060 |
Why?
|
| Ischemic Preconditioning, Myocardial | 2 | 2001 | 67 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2017 | 6191 | 0.060 |
Why?
|
| Telemetry | 1 | 2005 | 205 | 0.060 |
Why?
|
| Anti-HIV Agents | 1 | 2019 | 4250 | 0.060 |
Why?
|
| Apolipoproteins E | 1 | 2009 | 1438 | 0.060 |
Why?
|
| Acid-Base Equilibrium | 2 | 1983 | 185 | 0.060 |
Why?
|
| Femoral Neoplasms | 1 | 2003 | 77 | 0.060 |
Why?
|
| Heart Rupture, Post-Infarction | 1 | 2003 | 49 | 0.060 |
Why?
|
| Tibia | 1 | 2009 | 1075 | 0.060 |
Why?
|
| Community Health Services | 1 | 2008 | 650 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 3862 | 0.060 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2007 | 790 | 0.060 |
Why?
|
| Fibrinogen | 4 | 2004 | 894 | 0.060 |
Why?
|
| Urinary Bladder | 3 | 1985 | 1171 | 0.060 |
Why?
|
| Behavior Therapy | 1 | 2009 | 866 | 0.050 |
Why?
|
| Pulsatile Flow | 1 | 2004 | 332 | 0.050 |
Why?
|
| Hospital Information Systems | 1 | 2005 | 395 | 0.050 |
Why?
|
| Residence Characteristics | 2 | 2013 | 2049 | 0.050 |
Why?
|
| Medical Records | 2 | 2006 | 1413 | 0.050 |
Why?
|
| Guidelines as Topic | 4 | 2010 | 1402 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1985 | 2552 | 0.050 |
Why?
|
| Physician's Role | 2 | 2014 | 942 | 0.050 |
Why?
|
| Internal Fixators | 1 | 2003 | 188 | 0.050 |
Why?
|
| Triiodothyronine, Reverse | 1 | 1982 | 23 | 0.050 |
Why?
|
| Disaster Planning | 1 | 2008 | 549 | 0.050 |
Why?
|
| Neutrophil Activation | 1 | 2003 | 186 | 0.050 |
Why?
|
| Massachusetts | 4 | 2020 | 8662 | 0.050 |
Why?
|
| Marijuana Abuse | 1 | 2006 | 402 | 0.050 |
Why?
|
| Metabolic Diseases | 1 | 2009 | 657 | 0.050 |
Why?
|
| Academic Medical Centers | 2 | 2009 | 2749 | 0.050 |
Why?
|
| Equipment Design | 3 | 2008 | 3582 | 0.050 |
Why?
|
| Systole | 2 | 2017 | 956 | 0.050 |
Why?
|
| Health Care Costs | 4 | 2016 | 3203 | 0.050 |
Why?
|
| Statistics as Topic | 5 | 2009 | 2372 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 12220 | 0.050 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2007 | 740 | 0.050 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2002 | 141 | 0.050 |
Why?
|
| P-Selectin | 3 | 2017 | 600 | 0.050 |
Why?
|
| Blood Coagulation Disorders | 1 | 2004 | 337 | 0.050 |
Why?
|
| Reference Standards | 3 | 2012 | 1020 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2014 | 9185 | 0.050 |
Why?
|
| Vasodilation | 1 | 2005 | 944 | 0.050 |
Why?
|
| Recovery of Function | 2 | 2009 | 2924 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 4 | 2007 | 379 | 0.050 |
Why?
|
| Quality of Life | 3 | 2014 | 12730 | 0.050 |
Why?
|
| Osteosarcoma | 1 | 2007 | 880 | 0.050 |
Why?
|
| Hemodynamics | 5 | 2015 | 4197 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 14720 | 0.050 |
Why?
|
| Sweden | 2 | 2014 | 1343 | 0.050 |
Why?
|
| Hip Prosthesis | 1 | 2007 | 917 | 0.050 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2023 | 334 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 11472 | 0.050 |
Why?
|
| Peptic Ulcer | 2 | 2016 | 223 | 0.050 |
Why?
|
| Seasons | 2 | 2009 | 1492 | 0.050 |
Why?
|
| Genetic Variation | 3 | 2006 | 6540 | 0.050 |
Why?
|
| Referral and Consultation | 2 | 2013 | 3527 | 0.050 |
Why?
|
| Models, Statistical | 3 | 2011 | 5100 | 0.050 |
Why?
|
| Vaccines, Inactivated | 1 | 2021 | 184 | 0.050 |
Why?
|
| Calcium | 2 | 2021 | 5753 | 0.050 |
Why?
|
| Triiodothyronine | 1 | 1982 | 494 | 0.050 |
Why?
|
| Chlamydia Infections | 1 | 2003 | 364 | 0.050 |
Why?
|
| Spironolactone | 1 | 2023 | 382 | 0.050 |
Why?
|
| Serum Amyloid A Protein | 1 | 2000 | 121 | 0.040 |
Why?
|
| Amniotic Fluid | 1 | 1982 | 366 | 0.040 |
Why?
|
| Disease Reservoirs | 1 | 2020 | 131 | 0.040 |
Why?
|
| Dalteparin | 1 | 1999 | 42 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2015 | 3526 | 0.040 |
Why?
|
| Clinical Enzyme Tests | 1 | 1999 | 115 | 0.040 |
Why?
|
| Intra-Abdominal Fat | 1 | 2005 | 591 | 0.040 |
Why?
|
| Random Allocation | 3 | 2017 | 2425 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2006 | 1525 | 0.040 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2001 | 365 | 0.040 |
Why?
|
| District of Columbia | 1 | 2019 | 157 | 0.040 |
Why?
|
| Myocarditis | 1 | 2007 | 770 | 0.040 |
Why?
|
| Heart Rupture | 1 | 1999 | 23 | 0.040 |
Why?
|
| Product Labeling | 1 | 2020 | 79 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2007 | 997 | 0.040 |
Why?
|
| Microcirculation | 4 | 2006 | 1285 | 0.040 |
Why?
|
| Platelet Adhesiveness | 1 | 1999 | 161 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2001 | 1676 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 2006 | 1178 | 0.040 |
Why?
|
| Baltimore | 1 | 2019 | 231 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2022 | 674 | 0.040 |
Why?
|
| Calcinosis | 2 | 2005 | 1497 | 0.040 |
Why?
|
| Bariatric Surgery | 1 | 2009 | 940 | 0.040 |
Why?
|
| Pneumonia, Bacterial | 1 | 2002 | 316 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2009 | 3418 | 0.040 |
Why?
|
| Reperfusion | 1 | 2000 | 284 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2009 | 1914 | 0.040 |
Why?
|
| Relative Value Scales | 1 | 1999 | 84 | 0.040 |
Why?
|
| Kidney Neoplasms | 2 | 2007 | 4229 | 0.040 |
Why?
|
| Protons | 2 | 1983 | 1126 | 0.040 |
Why?
|
| South America | 1 | 2019 | 181 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2010 | 1895 | 0.040 |
Why?
|
| Wound Healing | 2 | 2006 | 2781 | 0.040 |
Why?
|
| Morbidity | 2 | 2016 | 1767 | 0.040 |
Why?
|
| Psychology, Educational | 1 | 1998 | 6 | 0.040 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2008 | 1341 | 0.040 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2004 | 532 | 0.040 |
Why?
|
| Transportation of Patients | 1 | 1999 | 185 | 0.040 |
Why?
|
| New Zealand | 1 | 2019 | 357 | 0.040 |
Why?
|
| Fishes | 1 | 2021 | 569 | 0.040 |
Why?
|
| Heart | 2 | 2003 | 4462 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2011 | 3439 | 0.040 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2020 | 417 | 0.040 |
Why?
|
| Insulin | 2 | 2023 | 6575 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2001 | 594 | 0.040 |
Why?
|
| Radionuclide Imaging | 2 | 1999 | 2027 | 0.040 |
Why?
|
| Monocytes | 1 | 2007 | 2593 | 0.040 |
Why?
|
| Virus Latency | 1 | 2020 | 356 | 0.040 |
Why?
|
| Anthropometry | 1 | 2002 | 1350 | 0.040 |
Why?
|
| Mycoses | 1 | 2020 | 376 | 0.040 |
Why?
|
| Potassium | 1 | 2021 | 1336 | 0.040 |
Why?
|
| Prodrugs | 1 | 1999 | 268 | 0.040 |
Why?
|
| Weight Loss | 1 | 2009 | 2604 | 0.040 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2020 | 247 | 0.040 |
Why?
|
| Antifibrinolytic Agents | 1 | 2000 | 254 | 0.040 |
Why?
|
| Sodium | 1 | 2022 | 1627 | 0.040 |
Why?
|
| Ablation Techniques | 1 | 2020 | 249 | 0.040 |
Why?
|
| Asia | 1 | 2019 | 607 | 0.040 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2007 | 1361 | 0.040 |
Why?
|
| Fibrinopeptide A | 1 | 1996 | 44 | 0.040 |
Why?
|
| Electric Countershock | 1 | 2020 | 535 | 0.040 |
Why?
|
| Muscles | 1 | 2022 | 1617 | 0.040 |
Why?
|
| Child | 6 | 2013 | 77478 | 0.040 |
Why?
|
| Surgical Wound Infection | 1 | 2006 | 1538 | 0.040 |
Why?
|
| Embolism | 1 | 2020 | 409 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2005 | 2739 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2009 | 2838 | 0.040 |
Why?
|
| Regional Blood Flow | 3 | 2008 | 1525 | 0.040 |
Why?
|
| Indians, North American | 1 | 2020 | 353 | 0.040 |
Why?
|
| Phospholipases A2 | 2 | 2007 | 202 | 0.040 |
Why?
|
| Antithrombin III | 1 | 1996 | 128 | 0.030 |
Why?
|
| Carbohydrate Metabolism | 1 | 2017 | 264 | 0.030 |
Why?
|
| Utah | 1 | 1996 | 126 | 0.030 |
Why?
|
| Prothrombin | 1 | 1996 | 185 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2020 | 1368 | 0.030 |
Why?
|
| Adrenomedullin | 1 | 2016 | 87 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2020 | 1341 | 0.030 |
Why?
|
| Turtles | 3 | 1985 | 40 | 0.030 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2016 | 55 | 0.030 |
Why?
|
| Transsexualism | 1 | 2019 | 177 | 0.030 |
Why?
|
| Genotype | 6 | 2010 | 12946 | 0.030 |
Why?
|
| Rhabdomyolysis | 1 | 2017 | 150 | 0.030 |
Why?
|
| Family Practice | 1 | 1999 | 516 | 0.030 |
Why?
|
| Fibrosis | 1 | 2022 | 2026 | 0.030 |
Why?
|
| Pharmacogenetics | 2 | 2010 | 676 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 425 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2007 | 2933 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2021 | 852 | 0.030 |
Why?
|
| Australia | 1 | 2019 | 1167 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2012 | 4551 | 0.030 |
Why?
|
| Neutrophils | 1 | 2008 | 3711 | 0.030 |
Why?
|
| Hernia, Diaphragmatic | 1 | 1996 | 250 | 0.030 |
Why?
|
| Medicare | 2 | 2010 | 6532 | 0.030 |
Why?
|
| Diastole | 1 | 2017 | 791 | 0.030 |
Why?
|
| Defibrillators, Implantable | 1 | 2004 | 1440 | 0.030 |
Why?
|
| Life Tables | 2 | 2006 | 370 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 914 | 0.030 |
Why?
|
| Glycopeptides | 1 | 2016 | 224 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2014 | 5662 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2021 | 1533 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2012 | 20086 | 0.030 |
Why?
|
| Models, Cardiovascular | 2 | 2003 | 994 | 0.030 |
Why?
|
| Contrast Media | 3 | 2003 | 5295 | 0.030 |
Why?
|
| Hypertension, Renal | 1 | 2015 | 177 | 0.030 |
Why?
|
| Blood Coagulation Factors | 1 | 1997 | 355 | 0.030 |
Why?
|
| Age of Onset | 1 | 2021 | 3266 | 0.030 |
Why?
|
| Hypotension | 1 | 2020 | 880 | 0.030 |
Why?
|
| Thromboxane-A Synthase | 1 | 1993 | 34 | 0.030 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 1996 | 425 | 0.030 |
Why?
|
| Intestinal Perforation | 1 | 2016 | 252 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2014 | 379 | 0.030 |
Why?
|
| Denervation | 1 | 2015 | 278 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 1997 | 1095 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2017 | 1146 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2017 | 4211 | 0.030 |
Why?
|
| Documentation | 1 | 2000 | 865 | 0.030 |
Why?
|
| Diarrhea | 1 | 2020 | 1343 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 1998 | 976 | 0.030 |
Why?
|
| Myocardium | 2 | 2004 | 4775 | 0.030 |
Why?
|
| Peptide Hydrolases | 1 | 1996 | 627 | 0.030 |
Why?
|
| Directive Counseling | 1 | 2014 | 166 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2014 | 1679 | 0.030 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2015 | 287 | 0.030 |
Why?
|
| Social Stigma | 1 | 2019 | 698 | 0.030 |
Why?
|
| Fee-for-Service Plans | 1 | 1998 | 694 | 0.030 |
Why?
|
| Chemical Precipitation | 1 | 2012 | 180 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 2013 | 288 | 0.030 |
Why?
|
| Cerebral Revascularization | 1 | 2015 | 238 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2020 | 2713 | 0.030 |
Why?
|
| Naproxen | 1 | 2013 | 99 | 0.030 |
Why?
|
| Retreatment | 2 | 2007 | 604 | 0.030 |
Why?
|
| Ultracentrifugation | 1 | 2012 | 182 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 2015 | 936 | 0.030 |
Why?
|
| Managed Care Programs | 1 | 1998 | 949 | 0.030 |
Why?
|
| Knowledge Management | 1 | 2012 | 6 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2009 | 15494 | 0.030 |
Why?
|
| Internationality | 1 | 2018 | 1002 | 0.030 |
Why?
|
| Pericardium | 3 | 2002 | 667 | 0.030 |
Why?
|
| Germany | 1 | 2014 | 860 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2005 | 5978 | 0.030 |
Why?
|
| Dextran Sulfate | 1 | 2012 | 236 | 0.030 |
Why?
|
| Intestinal Obstruction | 1 | 2016 | 424 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2007 | 3123 | 0.030 |
Why?
|
| Patient Participation | 1 | 2021 | 1445 | 0.030 |
Why?
|
| Heterozygote | 2 | 2009 | 2790 | 0.030 |
Why?
|
| Ibuprofen | 1 | 2013 | 235 | 0.030 |
Why?
|
| Hospital Bed Capacity | 1 | 2012 | 213 | 0.020 |
Why?
|
| Intermittent Claudication | 1 | 2014 | 309 | 0.020 |
Why?
|
| Haplotypes | 2 | 2009 | 2781 | 0.020 |
Why?
|
| Peer Review, Health Care | 1 | 2011 | 75 | 0.020 |
Why?
|
| Telecommunications | 1 | 2011 | 80 | 0.020 |
Why?
|
| Program Development | 1 | 1998 | 1314 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 1872 | 0.020 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 1996 | 578 | 0.020 |
Why?
|
| Catalysis | 1 | 2013 | 760 | 0.020 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2010 | 23 | 0.020 |
Why?
|
| Congenital Abnormalities | 1 | 1996 | 707 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2021 | 2275 | 0.020 |
Why?
|
| Neoplasms | 3 | 2017 | 21596 | 0.020 |
Why?
|
| Markov Chains | 1 | 2014 | 969 | 0.020 |
Why?
|
| Cyclosporine | 1 | 1993 | 784 | 0.020 |
Why?
|
| International Cooperation | 1 | 2017 | 1421 | 0.020 |
Why?
|
| Carotid Artery Thrombosis | 1 | 2010 | 53 | 0.020 |
Why?
|
| Fetal Diseases | 1 | 1996 | 903 | 0.020 |
Why?
|
| Mutation | 1 | 2015 | 29717 | 0.020 |
Why?
|
| Diet | 1 | 2009 | 7923 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2012 | 623 | 0.020 |
Why?
|
| Brazil | 1 | 2014 | 1263 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2012 | 648 | 0.020 |
Why?
|
| Disease Susceptibility | 2 | 2007 | 1780 | 0.020 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 5304 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2012 | 683 | 0.020 |
Why?
|
| Asthma | 1 | 2008 | 5955 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 1999 | 2128 | 0.020 |
Why?
|
| Receptors, Purinergic P2Y1 | 1 | 2009 | 40 | 0.020 |
Why?
|
| Goals | 1 | 2015 | 705 | 0.020 |
Why?
|
| Mice | 2 | 2017 | 81045 | 0.020 |
Why?
|
| Biotransformation | 1 | 2009 | 168 | 0.020 |
Why?
|
| Stress, Mechanical | 2 | 2008 | 1684 | 0.020 |
Why?
|
| Affect | 1 | 2017 | 1473 | 0.020 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2009 | 93 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2014 | 974 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 1995 | 3133 | 0.020 |
Why?
|
| Canada | 3 | 2002 | 2061 | 0.020 |
Why?
|
| Prenatal Diagnosis | 1 | 1996 | 1232 | 0.020 |
Why?
|
| Achievement | 1 | 2010 | 291 | 0.020 |
Why?
|
| Glipizide | 1 | 2008 | 47 | 0.020 |
Why?
|
| Pregnancy | 3 | 2020 | 29087 | 0.020 |
Why?
|
| Data Mining | 1 | 2013 | 537 | 0.020 |
Why?
|
| Kidney Tubules, Collecting | 1 | 1989 | 178 | 0.020 |
Why?
|
| Extremities | 1 | 2014 | 865 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2000 | 2527 | 0.020 |
Why?
|
| Learning | 1 | 1998 | 1705 | 0.020 |
Why?
|
| Connecticut | 1 | 2009 | 363 | 0.020 |
Why?
|
| Renin | 1 | 2010 | 642 | 0.020 |
Why?
|
| Bicarbonates | 1 | 1989 | 313 | 0.020 |
Why?
|
| Alleles | 3 | 2006 | 6931 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 2015 | 904 | 0.020 |
Why?
|
| Public Policy | 1 | 2012 | 572 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2012 | 780 | 0.020 |
Why?
|
| Biological Transport, Active | 2 | 1985 | 349 | 0.020 |
Why?
|
| Angiography | 2 | 2004 | 1636 | 0.020 |
Why?
|
| Chemistry, Clinical | 1 | 2007 | 64 | 0.020 |
Why?
|
| Boston | 1 | 2000 | 9305 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 3800 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 7770 | 0.020 |
Why?
|
| Health Maintenance Organizations | 1 | 2010 | 642 | 0.020 |
Why?
|
| Resuscitation | 1 | 2012 | 657 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2013 | 1124 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4379 | 0.020 |
Why?
|
| Evidence-Based Practice | 1 | 2012 | 500 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2013 | 2187 | 0.020 |
Why?
|
| Shock, Cardiogenic | 3 | 1999 | 684 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2011 | 1613 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 1989 | 486 | 0.020 |
Why?
|
| Feedback | 1 | 2011 | 793 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 10163 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 814 | 0.020 |
Why?
|
| Critical Illness | 2 | 2012 | 2665 | 0.020 |
Why?
|
| Age Distribution | 1 | 2013 | 2900 | 0.020 |
Why?
|
| Echocardiography | 1 | 1999 | 5097 | 0.020 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2012 | 963 | 0.020 |
Why?
|
| Weight-Bearing | 1 | 2009 | 514 | 0.020 |
Why?
|
| Acute-Phase Reaction | 1 | 2006 | 91 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2012 | 1132 | 0.020 |
Why?
|
| Colchicine | 2 | 1985 | 242 | 0.020 |
Why?
|
| Antibodies | 1 | 2015 | 2459 | 0.020 |
Why?
|
| Patient Rights | 1 | 2007 | 125 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1999 | 2099 | 0.020 |
Why?
|
| Hospitals, Community | 1 | 2008 | 348 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2007 | 587 | 0.020 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2009 | 585 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2008 | 419 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2010 | 681 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2007 | 841 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2012 | 1265 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 2077 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2007 | 1094 | 0.020 |
Why?
|
| Calcium Channel Blockers | 2 | 1999 | 689 | 0.020 |
Why?
|
| Oklahoma | 1 | 2004 | 37 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 4250 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2012 | 1206 | 0.020 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2004 | 25 | 0.020 |
Why?
|
| Therapeutics | 1 | 2005 | 116 | 0.020 |
Why?
|
| Calibration | 1 | 2007 | 815 | 0.020 |
Why?
|
| Homozygote | 1 | 2009 | 1777 | 0.020 |
Why?
|
| Diet, Reducing | 1 | 2008 | 461 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 4933 | 0.020 |
Why?
|
| Enzymes | 1 | 2006 | 266 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 1990 | 1599 | 0.010 |
Why?
|
| Erythrocyte Transfusion | 1 | 2009 | 565 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 1985 | 390 | 0.010 |
Why?
|
| Case Management | 1 | 2006 | 286 | 0.010 |
Why?
|
| Early Diagnosis | 1 | 2009 | 1184 | 0.010 |
Why?
|
| Propanolamines | 1 | 2004 | 167 | 0.010 |
Why?
|
| Hematologic Agents | 1 | 2004 | 39 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 9410 | 0.010 |
Why?
|
| H(+)-K(+)-Exchanging ATPase | 1 | 1983 | 36 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1993 | 13814 | 0.010 |
Why?
|
| Private Practice | 1 | 2004 | 154 | 0.010 |
Why?
|
| Membrane Fusion | 1 | 1985 | 273 | 0.010 |
Why?
|
| Lung | 1 | 1982 | 9826 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 2004 | 318 | 0.010 |
Why?
|
| Cell Separation | 1 | 1989 | 1749 | 0.010 |
Why?
|
| African Americans | 1 | 2002 | 23 | 0.010 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2005 | 213 | 0.010 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2008 | 591 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 2007 | 668 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2004 | 613 | 0.010 |
Why?
|
| Fees, Pharmaceutical | 1 | 2002 | 64 | 0.010 |
Why?
|
| Carbazoles | 1 | 2004 | 226 | 0.010 |
Why?
|
| Pandemics | 1 | 2023 | 8328 | 0.010 |
Why?
|
| Prejudice | 1 | 2007 | 569 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2004 | 297 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1993 | 18112 | 0.010 |
Why?
|
| Observer Variation | 1 | 2008 | 2593 | 0.010 |
Why?
|
| Geriatrics | 1 | 2007 | 396 | 0.010 |
Why?
|
| Fetal Organ Maturity | 1 | 1982 | 82 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2017 | 14554 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 2006 | 603 | 0.010 |
Why?
|
| Neoplasm Staging | 2 | 2007 | 11001 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2019 | 4440 | 0.010 |
Why?
|
| Superoxides | 1 | 2003 | 386 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2007 | 1093 | 0.010 |
Why?
|
| Antigens, Human Platelet | 1 | 2001 | 43 | 0.010 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2009 | 1016 | 0.010 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 1183 | 0.010 |
Why?
|
| Polysaccharides | 1 | 2008 | 1051 | 0.010 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2007 | 783 | 0.010 |
Why?
|
| Minisatellite Repeats | 1 | 2002 | 165 | 0.010 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2004 | 476 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 2000 | 193 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 4771 | 0.010 |
Why?
|
| Pain | 1 | 2016 | 4961 | 0.010 |
Why?
|
| Urine | 1 | 1982 | 370 | 0.010 |
Why?
|
| Intraoperative Complications | 1 | 2007 | 1188 | 0.010 |
Why?
|
| Collateral Circulation | 1 | 2001 | 287 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2007 | 1183 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2004 | 1589 | 0.010 |
Why?
|
| Minority Groups | 1 | 2008 | 1215 | 0.010 |
Why?
|
| Anemia | 1 | 2009 | 1499 | 0.010 |
Why?
|
| Rheology | 1 | 2000 | 345 | 0.010 |
Why?
|
| Amidines | 1 | 1999 | 30 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2006 | 1296 | 0.010 |
Why?
|
| Leukocytosis | 1 | 2000 | 247 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 21821 | 0.010 |
Why?
|
| Government Agencies | 1 | 2000 | 156 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2008 | 1636 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 1 | 1983 | 836 | 0.010 |
Why?
|
| Endocytosis | 1 | 1983 | 983 | 0.010 |
Why?
|
| Nitrites | 1 | 1999 | 160 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2008 | 5062 | 0.010 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2002 | 232 | 0.010 |
Why?
|
| Epithelium | 1 | 1983 | 1680 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 1993 | 4246 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2007 | 35342 | 0.010 |
Why?
|
| Complement C4 | 1 | 1999 | 257 | 0.010 |
Why?
|
| Blood Sedimentation | 1 | 1999 | 231 | 0.010 |
Why?
|
| Choice Behavior | 1 | 2004 | 802 | 0.010 |
Why?
|
| Heterocyclic Compounds | 1 | 1999 | 249 | 0.010 |
Why?
|
| Infection Control | 1 | 2005 | 962 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 3507 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2001 | 1799 | 0.010 |
Why?
|
| Plasminogen | 1 | 1998 | 152 | 0.010 |
Why?
|
| Hemorheology | 1 | 1997 | 145 | 0.010 |
Why?
|
| Internet | 1 | 2010 | 3062 | 0.010 |
Why?
|
| Antibodies, Antinuclear | 1 | 1999 | 326 | 0.010 |
Why?
|
| Information Services | 1 | 1999 | 244 | 0.010 |
Why?
|
| Nitrates | 1 | 1999 | 265 | 0.010 |
Why?
|
| Nitroglycerin | 1 | 1998 | 325 | 0.010 |
Why?
|
| Complement C3 | 1 | 1999 | 460 | 0.010 |
Why?
|
| Medicaid | 1 | 2010 | 2716 | 0.010 |
Why?
|
| Orthopedic Procedures | 1 | 2007 | 1288 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 3391 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2001 | 1727 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2000 | 780 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2007 | 1825 | 0.010 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 1996 | 176 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2003 | 20774 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1996 | 25575 | 0.010 |
Why?
|
| Leadership | 1 | 2005 | 1357 | 0.010 |
Why?
|
| Cost Control | 1 | 1998 | 624 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 2007 | 1873 | 0.010 |
Why?
|
| Selection Bias | 1 | 1997 | 369 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2005 | 1884 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1995 | 918 | 0.010 |
Why?
|
| Autoimmunity | 1 | 2002 | 1348 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2002 | 2036 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2007 | 40955 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2017 | 23387 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4751 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 1999 | 1585 | 0.010 |
Why?
|
| Mental Health Services | 1 | 2005 | 1643 | 0.010 |
Why?
|
| Thromboxane B2 | 1 | 1993 | 152 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2002 | 2260 | 0.010 |
Why?
|
| Hemostasis | 1 | 1996 | 458 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2001 | 2751 | 0.010 |
Why?
|
| Italy | 1 | 1995 | 828 | 0.010 |
Why?
|
| Neutropenia | 1 | 1998 | 891 | 0.010 |
Why?
|
| Women's Health | 1 | 2002 | 2034 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 16331 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2003 | 2217 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1999 | 3471 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1990 | 878 | 0.010 |
Why?
|
| 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid | 1 | 1989 | 34 | 0.010 |
Why?
|
| 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 1989 | 60 | 0.010 |
Why?
|
| DNA Probes | 1 | 1990 | 560 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 1086 | 0.010 |
Why?
|
| Capillaries | 1 | 1990 | 774 | 0.000 |
Why?
|
| Sodium Channels | 1 | 1989 | 349 | 0.000 |
Why?
|
| Immunoblotting | 1 | 1990 | 1683 | 0.000 |
Why?
|
| Research | 1 | 1995 | 1999 | 0.000 |
Why?
|
| Chlorides | 1 | 1989 | 667 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 17400 | 0.000 |
Why?
|
| Organ Specificity | 1 | 1990 | 2003 | 0.000 |
Why?
|
| Infant | 1 | 2007 | 35070 | 0.000 |
Why?
|
| Cloning, Molecular | 1 | 1990 | 4322 | 0.000 |
Why?
|
| Cross-Sectional Studies | 1 | 2005 | 24913 | 0.000 |
Why?
|
| Cattle | 1 | 1990 | 3923 | 0.000 |
Why?
|
| Cells, Cultured | 2 | 1990 | 19223 | 0.000 |
Why?
|
| Rabbits | 1 | 1989 | 4886 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1990 | 6171 | 0.000 |
Why?
|
| Cerebrovascular Circulation | 1 | 1990 | 2732 | 0.000 |
Why?
|
| Base Sequence | 1 | 1990 | 12797 | 0.000 |
Why?
|
| DNA | 1 | 1990 | 7289 | 0.000 |
Why?
|
| Cell Line | 1 | 1990 | 15994 | 0.000 |
Why?
|